This section includes information and resources about Stroke Prevention in Atrial Fibrillation (AF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos. For additional information please visit Newshome.
Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
New data on safety and efficacy of Pradaxa® in treatment of acute deep vein thrombosis and pulmonary embolism
New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism*
Pradaxa® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY® – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do not change the position of Pradaxa®
New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years
Preventing AF related strokes is vital. Protecting your brain protects your world.